Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited, partly related to some of their pharmacologic properties. To overcome these challenges, our group had previou...
Main Authors: | Yung-Hsing Huang, Mohammad Reza Vakili, Ommoleila Molavi, Yuen Morrissey, Chengsheng Wu, Igor Paiva, Amir Hasan Soleimani, Forugh Sanaee, Afsaneh Lavasanifar, Raymond Lai |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/11/2/248 |
Similar Items
-
Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model
by: Yung-Hsing Huang, et al.
Published: (2018-06-01) -
Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism
by: Yung-Hsing Huang, et al.
Published: (2021-06-01) -
STAT3: A Promising Therapeutic Target in Multiple Myeloma
by: Phyllis S. Y. Chong, et al.
Published: (2019-05-01) -
Development of polymeric micelles loaded with STAT3 inhibitory, Stattic, for cancer treatment
by: Hamed Masoumzadeh, et al.
Published: (2021-10-01) -
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
by: Torben Plesner, et al.
Published: (2020-02-01)